Upcoming event

Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer

2022-06-16

Prof. Davis elaborates on the ENZAMET trial, the design and updated results of this trial, as well as the overall survival benefit in mHSPC with the addition of enzalutamide.